Navigation Links
Type 2 diabetes patients transplanted with own bone marrow stem cells reduces insulin use
Date:6/28/2013

Putnam Valley, NY. (June 28 2013) A study carried out in India examining the safety and efficacy of self-donated (autologous), transplanted bone marrow stem cells in patients with type 2 diabetes (TD2M), has found that patients receiving the transplants, when compared to a control group of TD2M patients who did not receive transplantation, required less insulin post-transplantation.

The study appears as an early e-publication for the journal Cell Transplantation, and is now freely available on-line at http://www.ingentaconnect.com/content/cog/ct/pre-prints/ct0920bhansali.

"There is growing interest in the scientific community for cellular therapies that use bone marrow-derived cells for the treatment of type 2 diabetes mellitus and its complications," said study corresponding author Anil Bhansali, PhD professor and head of the Endocrinology Department at the Post Graduate Institute of Medical Education in Chandrigarh, India. "But the potential of stem cell therapy for this disease is yet to be fully explored."

While there is growing interest in using stem cell transplantation to treat TD2M, few studies have examined the utility of bone marrow-derived stem cells. By experimenting with bone marrow-derived stem cells, the researchers sought to exploit the rich source of stem cells in bone marrow.

Their study aimed at evaluating the efficacy and safety of autologous bone marrow-derived stem cell transplantation in patients with T2DM and who also had good glycemic control. Good glycemic control emerged as an important factor in the transplantation group and in the non-transplanted control group.

Cell transplantation had a significant impact on the patients in this study as those administered cells demonstrated a significant reduction in insulin requirement. A significantly smaller reduction in the insulin requirement of the control group was also observed but a "repeated emphasis on life style modification" was believed to be a contributing factor in this effect.

According to Dr. Bhansali, the strength of their study included the inclusion of a homogenous patient population with T2DM which exhibited good glycemic control, and the presence of a similar control group that did not get cell transplants.

"The efficacy and safety of stem cell therapy needs to be established in a greater number of patients and with a longer duration follow-up," concluded Bhansali and his co-authors. "The data available so far from animal and human studies is encouraging, however, it has enormous limitations."

The researchers recommended determining which type of stem cells -hematopoietic, bone marrow or placenta-derived - might be best to treat T2DM. In addition, they said that post-transplantation patients needed close monitoring for the development of neoplasia as stem cells - whether multipotent or pluripotent - have the potential for malignant transformation.

They concluded that "autologous bone marrow-derived stem cell therapy in patients with T2DM results in significant decrease in insulin dose requirement."


'/>"/>

Contact: Robert Miranda
cogcomm@aol.com
Cell Transplantation Center of Excellence for Aging and Brain Repair
Source:Eurekalert

Related biology news :

1. National Institutes of Health to fund research probing proteins linked to cancer, diabetes
2. Mercy Lab Offers Faster On-demand Diabetes Testing, Cellular Studies
3. New data on islet autoantibodies in young children defines early type 1 diabetes development
4. Breakthrough research of essential molecule reveals important targets in diabetes and obesity
5. From autism to diabetes to Parkinsons disease
6. Nanotechnology could help fight diabetes
7. Discovery of new hormone opens doors to new type 2 diabetes treatments
8. Co-Q10 deficiency may relate to concern with statin drugs, higher risk of diabetes
9. Our internal clocks can become ticking time bombs for diabetes and obesity
10. BUSM study reveals therapeutic targets to alter inflammation, type 2 diabetes
11. Shiner Beers launches nationwide support of TGen diabetes studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2016)... -- Cercacor today introduced Ember TM Sport Premium ... measure hemoglobin, Oxygen Content, Oxygen Saturation, Perfusion Index, ... approximately 30 seconds. Smaller than a smartphone, using only ... key data about their bodies to help monitor these ... Hemoglobin carries oxygen to muscles. When hemoglobin and ...
(Date:11/19/2016)... Securus Technologies, a leading provider of civil and criminal ... monitoring, announced today that it has offered a challenge ... technology judge determine who has the largest and best ... platform, and the best customer service. "ICSolutions ... we do – which clearly is not the case ...
(Date:11/15/2016)... ROCKVILLE, Md. , Nov. 15, 2016 /PRNewswire/ ... clinical company developing therapeutics focused on the gut ... public offering of 25,000,000 shares of its common ... its common stock at a price to the ... gross proceeds to Synthetic Biologics from the offering, ...
Breaking Biology News(10 mins):
(Date:12/6/2016)... and SAN DIEGO , Dec. 6, ... appointment of Santosh Kesari , MD, PhD, FANA, ... leverage his experience in neurology and clinical trials to ... cell for treatment of stroke. The AmnioStem product is a ... has previously shown therapeutic activity in animal models of ...
(Date:12/6/2016)... , Dec. 6, 2016  SRI International has ... million from the National Institutes of Health,s National ... Division of AIDS (NIAID-DAIDS) to support the manufacturing ... pre-exposure (PreP) agents. Under the seven-year contract, SRI ... development services for candidate HIV-prevention products that emerge ...
(Date:12/6/2016)... ... December 06, 2016 , ... ... company focused on discovery and development of precision treatments for neurodegenerative diseases, ... for Alzheimer’s disease (AD) inhibited the direct neurotoxic effect of prion-like forms ...
(Date:12/5/2016)... Dec. 5, 2016 Axovant Sciences Ltd. (NYSE: ... focused on the treatment of dementia, today announced that ... treatment of Alzheimer,s disease will be presented at the ... Friday, December 9, 2016 in San Diego ... of both simple and complex measures of activities of ...
Breaking Biology Technology: